Home » News » Scancell IPO nets Oxford Capital 20% return

Scancell IPO nets Oxford Capital 20% return

Marc Barberby Marc Barber


Venture capitalist Oxford Capital has seen the value of its holding in cancer vaccine specialist Scancell Holdings increase by 20 per cent following the company’s float on London’s PLUS Market

Marc Barber

Marc Barber

Marc was editor of GrowthBusiness from 2006 to 2010. He specialised in writing about entrepreneurs, private equity and venture capital, mid-market M&A, small caps and high-growth businesses.

Related Stories

News

General Election 2024 – what do scale-ups want to see?

The General Election will be on July 4, 2024, with political parties scrambling to get their policies together. What do high-growth firms want?

News

ThinCats to back high-growth companies with £300m fund

The new fund is for high-growth and owner-managed businesses based in London, the South East, North West and the Midlands

News

Fastest-growing companies in the UK revealed

The eighth annual FT1000 rankings is based on revenue growth in the three years to 2022

News

Litestream Ventures unveils plans for ‘click-to-invest’ TV series  

The venture media firm is hoping the series will challenge the likes of Dragons’ Den

Related Topics

Oxford Capital